List of Excipients in Branded Drug TRIOSTAT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Par Pharmaceutical Inc	TRIOSTAT	liothyronine sodium	42023-120	ALCOHOL
Par Pharmaceutical Inc	TRIOSTAT	liothyronine sodium	42023-120	AMMONIA
Par Pharmaceutical Inc	TRIOSTAT	liothyronine sodium	42023-120	ANHYDROUS CITRIC ACID

Last updated: August 20, 2026

IOSTAT excipient strategy is a formulation and supply-chain opportunity, not a conventional patent-led opportunity. The product is liothyronine sodium injection, a sterile parenteral treatment for myxedema coma and severe hypothyroidism. Its commercial value depends on reliable sterile manufacturing, low-dose accuracy, stability, hospital procurement, and emergency availability. The strongest opportunities are ready-to-use presentations, improved shelf life, syringe formats, differentiated concentrations, and supply reliability rather than complex excipient innovation.

TRIOSTAT Excipient Strategy, Patent Position, and Commercial Opportunities

What is TRIOSTAT and what formulation does it use?

TRIOSTAT is an injectable formulation of liothyronine sodium, the sodium salt of synthetic triiodothyronine, or T3. It is administered intravenously when rapid thyroid-hormone replacement is required, particularly in myxedema coma or severe hypothyroidism.

The historical TRIOSTAT presentation is a sterile aqueous injection containing 10 mcg of liothyronine sodium per mL. The product is supplied for parenteral administration and is intended for use in hospital or emergency-care settings. The formulation uses a simple excipient system designed to maintain solubility, pH control, isotonicity, and chemical stability rather than to create extended release or targeted delivery.[1]

TRIOSTAT formulation profile

Attribute	Commercial relevance
Active ingredient	Liothyronine sodium
Pharmacological class	Thyroid hormone replacement
Dosage form	Sterile injectable solution
Administration	Intravenous; hospital use
Historical concentration	10 mcg/mL
Primary use	Myxedema coma and severe hypothyroidism
Formulation type	Aqueous, immediate-release parenteral solution
Preservative strategy	Preferably preservative-free for emergency intravenous use
Key technical risks	Low-dose assay accuracy, adsorption, oxidation, pH drift, particulate control
Primary commercial constraint	Limited hospital demand and sterile injectable manufacturing complexity

The applicable label should control the current excipient composition, strength, packaging, storage conditions, and FDA marketing status. Historical product descriptions identify sodium chloride and pH-adjusting agents among the formulation components, but excipient composition can vary by sponsor, manufacturing site, and approved presentation.[1]

What excipients are strategically important for TRIOSTAT?

The most important excipients are those that support solubility, isotonicity, pH control, and stability at very low drug concentration.

Sodium chloride and tonicity control

Sodium chloride can provide isotonicity and help reduce the risk of local irritation during intravenous administration. The formulation target should be established through osmolality testing rather than by assuming that sodium chloride concentration alone will produce a physiologically acceptable product.

A commercial reformulation should avoid unnecessary tonicity excursions. Emergency-use products may be administered through peripheral lines, central lines, or infusion systems, so excessive osmolality could create a practical hospital-use disadvantage.

pH-adjusting agents

Liothyronine sodium is sensitive to formulation conditions that affect solubility and chemical stability. Hydrochloric acid or sodium hydroxide may be used to adjust pH during manufacturing. The commercial opportunity is not the presence of a conventional pH adjuster. It is the selection of a pH range that improves stability without increasing degradation, precipitation, or injection-site risk.

A sponsor seeking formulation differentiation should generate comparative data on:

• Assay and related substances across the proposed pH range
• Stability after dilution in common intravenous fluids
• Container-closure interaction
• Light exposure
• Freeze-thaw stress
• Agitation and transport stress
• Compatibility with infusion bags, tubing, and syringes

Water for injection

Water for Injection is the principal vehicle for the aqueous product. Its use imposes standard requirements for sterility, endotoxin control, particulate matter, and container-closure integrity under FDA regulations governing parenteral products.[2]

Preservative choice

A preservative-free presentation is commercially attractive because TRIOSTAT is used intravenously in acutely ill patients. Multidose formats could reduce packaging cost but create additional concerns involving antimicrobial effectiveness, repeated vial entry, dosing accuracy, and hospital infection-control policies.

A preservative-based formulation would need a clear use-case, such as a multidose emergency-stock presentation. The regulatory and clinical burden would likely outweigh the benefit unless the product materially reduces waste or improves availability.

Chelators and antioxidants

Chelators or antioxidants could be considered if degradation studies demonstrate oxidation or metal-catalyzed instability. Their use would require evidence that they do not alter liothyronine potency, compatibility, safety, or analytical performance.

A minimal-excipient formulation is strategically preferable. Every additional excipient increases the number of extractables, leachables, compatibility, toxicology, and regulatory questions. For a low-volume emergency injectable, excipient complexity has limited commercial upside unless it produces a measurable stability or packaging benefit.

What excipient strategies could improve TRIOSTAT?

Ready-to-use prefilled syringes

A prefilled syringe is the most commercially visible opportunity. It could reduce preparation time and dose-conversion errors in emergency care. A 10 mcg/mL syringe could be offered in a small-volume configuration aligned with common loading and maintenance doses.

Key development issues include:

• Syringe material and silicone-oil interaction
• Adsorption of liothyronine to syringe components
• Needle and tip-cap compatibility
• Delivered-volume accuracy
• Stability during refrigerated and room-temperature storage
• Protection from light
• Human-factors validation
• Compatibility with automated medication cabinets

The principal value would come from workflow and safety improvement, not from a novel excipient alone.

Dual-strength products

A second concentration could reduce dilution steps for hospitals. Potential formats include a lower concentration for titrated administration and a higher concentration for loading doses. The risk is medication error caused by similar packaging or concentration confusion.

A dual-strength portfolio would need strong labeling differentiation, barcode controls, and evidence that the concentration improves clinical workflow. The commercial case is strongest if hospitals currently dilute a standard concentration before administration.

Improved light protection

A light-protective vial, syringe, or secondary package could support longer shelf life and reduce pharmacy handling restrictions. This strategy is relatively low risk because it can rely on packaging changes rather than a new excipient system.

The sponsor should evaluate amber glass, ultraviolet-blocking polymer, foil overwraps, and secondary cartons. The preferred option should balance light protection with visual inspection for particles and discoloration.

Refrigeration reduction

A product that remains stable at controlled room temperature would have a meaningful hospital advantage. Emergency departments, ambulances, crash carts, and remote facilities benefit from reduced cold-chain dependence.

A room-temperature formulation could be differentiated through:

• Buffer optimization
• Oxygen-control packaging
• Headspace management
• Improved container closure
• Light-protective packaging
• Lower adsorption surfaces

Any claim of improved temperature stability would require real-time and accelerated stability data under the applicable FDA drug-product requirements.[3]

Lyophilized formulation

A lyophilized liothyronine product could improve long-term stability, but it would add reconstitution steps and increase the risk of administration errors. It would be commercially attractive only if the liquid formulation has a material stability limitation that cannot be solved through packaging or pH optimization.

For emergency use, a stable liquid is generally operationally superior to a powder requiring reconstitution.

What patents protect TRIOSTAT and its excipient strategy?

TRIOSTAT is based on an established small-molecule active ingredient and a conventional injectable dosage form. The main opportunity is unlikely to depend on broad composition-of-matter protection for liothyronine sodium.

Potential intellectual-property categories include:

1. Specific injectable compositions
2. Defined pH and buffer systems
3. Stabilized aqueous formulations
4. Prefilled syringe configurations
5. Light-protective packaging
6. Container-closure systems
7. Dosing regimens for myxedema coma
8. Methods for reducing preparation errors
9. Manufacturing processes that improve assay uniformity or stability

An excipient patent would need a narrow technical relationship between the excipient system and a measurable benefit, such as improved stability, reduced adsorption, lower particulate formation, or enhanced room-temperature storage.

Broad claims covering liothyronine sodium in water with standard tonicity or pH agents would face substantial prior-art and obviousness pressure. A stronger patent strategy would combine:

• A defined liothyronine concentration
• A narrow pH range
• A specified excipient ratio
• A particular container material
• A demonstrated degradation profile
• A stability period that exceeds known products

The Orange Book should be reviewed for the current reference-listed-drug status and any listed patents or exclusivity. Patent protection cannot be inferred from the existence of the TRIOSTAT brand or from historical labeling alone.[4]

When does TRIOSTAT lose exclusivity?

TRIOSTAT’s commercial exclusivity is principally limited by the age of the active ingredient and the availability of generic regulatory pathways. Liothyronine is an established small molecule, so the relevant barriers are likely to be formulation approval, sterile manufacturing, clinical bridging, and market economics rather than new chemical-entity exclusivity.

A generic or alternative sponsor could pursue an abbreviated application if the proposed product meets the applicable requirements for sameness, strength, dosage form, route, quality, and bioequivalence. Where an injectable product has no meaningful pharmacokinetic bioequivalence pathway or where formulation differences are significant, a 505(b)(2) application may provide a more practical route.[5]

Generic entry scenarios

Scenario	Regulatory route	Commercial effect
Same-strength aqueous injection	ANDA, if requirements are met	Direct price competition
Different excipient system	ANDA or 505(b)(2), depending on differences	Potential formulation differentiation
Prefilled syringe	505(b)(2) or other applicable pathway	Workflow and safety positioning
New concentration	505(b)(2) likely more relevant	Expanded dosing convenience
Lyophilized product	505(b)(2) likely	Stability benefit, added preparation burden
Compounded hospital supply	Not equivalent to FDA-approved commercial product	Local supply alternative, variable quality controls

Does TRIOSTAT have biosimilar risk?

No. TRIOSTAT contains liothyronine sodium, a chemically synthesized small molecule. It is not a biologic and does not face biosimilar competition under the Public Health Service Act. Competitive products would be generics, reformulations, 505(b)(2) products, or pharmacy-compounded preparations rather than biosimilars.[6]

What is the FDA regulatory status of TRIOSTAT?

TRIOSTAT is associated with the FDA’s drug approval framework for liothyronine sodium injection. The current regulatory status should be confirmed through FDA Drugs@FDA, the Orange Book, and the relevant current labeling record because historical brands can be discontinued, transferred, relabeled, or replaced by generic products.[4,7]

The regulatory opportunity is strongest for a sponsor that can establish an approved, consistently available injectable product with:

• Current good manufacturing practice compliance
• Validated sterile processing
• Reliable low-dose analytical methods
• Container-closure integrity
• Demonstrated stability
• Clear hospital dosing instructions
• Adequate supply continuity

FDA drug shortages and discontinuation records are commercially relevant because hospitals may value dependable supply more than modest formulation novelty.[7]

What commercial opportunities exist for TRIOSTAT?

Hospital emergency-market positioning

The product addresses a low-frequency but high-acuity indication. Hospitals need reliable access even when annual unit demand is modest. Commercial positioning should focus on emergency departments, intensive-care units, endocrinology services, pharmacy departments, and emergency medication stock.

Contract manufacturing and supply partnerships

A sponsor without sterile injectable capacity could pursue a contract manufacturing organization with experience in:

• Low-dose aqueous injections
• Terminal sterilization or aseptic processing
• Glass vial and prefilled syringe filling
• Cold-chain and controlled-room-temperature products
• Small-batch, low-volume commercial production

A supply agreement with a hospital distributor or group purchasing organization could be more valuable than a conventional consumer marketing campaign.

Regional supply security

Hospitals may pay a premium for a second source when a product has a narrow supplier base. A differentiated product could target markets where thyroid hormone injectable supply is inconsistent, subject to local regulatory approval and reimbursement rules.

Bundled emergency-care products

A sponsor could package liothyronine injection with dosing aids, barcode-ready labeling, and standardized administration instructions. The underlying drug remains conventional, but the hospital-use system could support brand preference.

Revenue exposure

Revenue potential is constrained by the narrow indication and low administration volume. The product is unlikely to support large primary-care revenue unless a sponsor expands into other liothyronine dosage forms or thyroid-related products.

The most credible commercial model is a specialty injectable portfolio with shared manufacturing, distribution, and hospital contracting infrastructure. Stand-alone investment in a complex new excipient platform would face a weak return profile unless it supports multiple injectable products.

How strong is the TRIOSTAT patent estate?

The likely patent estate is moderate to weak for the core product and potentially stronger for a genuinely differentiated presentation. The active ingredient is old, and conventional excipients provide limited room for broad exclusivity.

Patent-strength assessment

IP category	Likely strength	Reason
Liothyronine composition of matter	Low	Established active ingredient
Conventional aqueous injection	Low	Predictable formulation architecture
Narrow pH and excipient combination	Moderate	Depends on unexpected stability data
Prefilled syringe system	Moderate	Stronger if tied to stability and dosing benefits
Light-protective packaging	Low to moderate	Potential design-around risk
Room-temperature stability	Moderate to strong	Depends on comparative data and claim scope
Method-of-use claims	Variable	Clinical evidence and prior art are critical
Manufacturing process	Moderate	Stronger if process materially improves quality

What patent litigation and Paragraph IV risks exist?

A Paragraph IV challenge could arise if an Orange Book-listed patent covers a formulation, use, or delivery system. The practical risk depends on the current listed patents, their expiration dates, certifications, and any litigation filed by the reference sponsor.

For a conventional liothyronine sodium injection, the principal legal risks are likely to involve formulation patents, labeling differences, and regulatory exclusivity rather than active-ingredient patents. A generic sponsor should assess:

• Orange Book patent listings
• Patent term adjustment
• Pediatric exclusivity
• Method-of-use carve-outs
• Section viii statements
• Prior ANDA approvals
• Patent litigation under the Hatch-Waxman Act
• Any settlement restricting launch timing

Without a currently identified listed patent, the larger risk is market-entry execution: sterile manufacturing validation, FDA review, supply continuity, and hospital adoption.

Key Takeaways

• TRIOSTAT is liothyronine sodium injection for acute thyroid-hormone replacement.
• The highest-value excipient priorities are pH control, tonicity, low-dose stability, adsorption control, and light protection.
• Preservative-free, ready-to-use presentations are commercially attractive for hospital emergency use.
• Prefilled syringes and improved room-temperature stability offer stronger differentiation than adding multiple excipients.
• TRIOSTAT has no biosimilar risk because liothyronine sodium is a small molecule.
• Generic and 505(b)(2) competition is more relevant than biologic competition.
• Core formulation patent strength is likely limited unless a sponsor demonstrates unexpected stability or delivery advantages.
• The strongest commercial opportunity is a reliable sterile injectable supply platform supported by hospital contracting and differentiated packaging.
• Revenue is constrained by the narrow emergency indication, so manufacturing and distribution economics are critical.

FAQs

Can a new TRIOSTAT formulation use a different buffer?

Yes, provided the sponsor demonstrates pharmaceutical quality, stability, compatibility, safety, and regulatory acceptability. A different buffer may support a 505(b)(2) strategy if it creates clinically or technically meaningful differences.

Is a preservative-free TRIOSTAT syringe commercially feasible?

Yes. A preservative-free prefilled syringe could reduce preparation steps and support emergency use, but the sponsor must address adsorption, syringe compatibility, delivered-volume accuracy, sterility, and shelf life.

Could TRIOSTAT be supplied in an autoinjector?

An autoinjector is technically possible but commercially difficult. Intravenous administration, very low dose volume, hospital supervision, and emergency dosing requirements make a conventional prefilled syringe more practical.

Would a lyophilized liothyronine product obtain meaningful market protection?

It could obtain formulation or regulatory differentiation if it demonstrates a material stability benefit. Its commercial value would be reduced by the need for reconstitution and the resulting medication-error risk.

Can a compounded liothyronine injection replace an FDA-approved product?

Compounded products may provide local supply alternatives, but they are not automatically therapeutically or regulatorily interchangeable with an FDA-approved commercial injection. Hospitals generally assess sterility, quality controls, availability, and institutional policy before relying on compounded supply.

References

1. U.S. Food and Drug Administration. (n.d.). TRIOSTAT (liothyronine sodium) injection prescribing information. Drugs@FDA and product labeling records.

2. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 211: Current good manufacturing practice for finished pharmaceuticals.

3. U.S. Food and Drug Administration. (2003). Guidance for industry: Q1A(R2) stability testing of new drug substances and products.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.

5. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2).

6. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biologic products.

7. U.S. Food and Drug Administration. (2024). Drug shortages and discontinued drugs database.